The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The CDC's newly reconstituted Advisory Committee on Immunization Practices (ACIP) voted 5-2 in support of infants younger ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

RSV is ubiquitous. Nearly everyone has been infected with the virus before age 2, the US Centers for Disease Control and Prevention says. Infection usually causes symptoms that look a lot like a ...